The cases of 3 female patients with metastatic
breast cancer treated with oral UFT and
cyclophosphamide (CPA) are reported. Patient 1 had lymph node and bone
metastases. Patient 2 had bone
metastasis. Patient 3 had skin, lymph node, and peritoneal
metastases. All had a history of
mastectomy and chemo- and/or endocrine
therapy for metastatic lesions. Patients 2 and 3 had also undergone CAF
combination chemotherapy. However, the lesions did not change. UFT 400 mg and CPA 100 mg, everyday, were administered to patient
1. UFT 400 mg and CPA 100 mg, 2 weeks, and UFT 400 mg, 2 weeks, were given every 4 weeks to patient 2. UFT 300 mg and CPA 150 mg, 6 weeks per 8 weeks were given to patient 3. Improvements in the metastatic lesions were seen 4 weeks after the beginning of UFT and CPA
therapy.
Therapy is now continuing, and no patients had a progression of the disease. All had
leukopenia 2 or 4 weeks after the beginning of this
therapy, and two temporarily stopped the
therapy. No other side-effect was observed. Oral UFT and CPA combination
therapy was considered useful for metastatic
breast cancer. To prevent
leukopenia and prolong the term of treatment efficacy, a treatment regimen will need to be established.